Pfizer dividend history
Pfizer's dividend was $1.72 a share in fiscal 2025, up 1.8% on the year before. That was 125.7% of net income. It has raised its dividend per share every year since fiscal 2010, as far back as our figures go.
Dividends, buybacks and capital spending
- Dividends (TTM)
- $9.8B
- Diluted share count
- +0.3%
- year over year
- Total shareholder yield
- 5.5%
- dividends 5.5% + buybacks 0.0% of market value
- Dividend payout ratio
- 243%
- of net income paid out
- R&D spending
- 18.1%
- of revenue
- Sales & admin spending
- 21.7%
- of revenue
- Days sales outstanding
- 81 days
- receivables vs revenue
Dividends by fiscal year
| Fiscal year | 2007Dec 2007 | 2008Dec 2008 | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend per share | — | — | — | $0.720 | $0.800 | $0.880 | $0.960 | $1.22 | $1.30 | $1.38 | $1.46 | $1.53 | $1.57 | $1.61 | $1.65 | $1.69 | $1.72 | — |
| Dividend per share growth | — | — | — | — | +11.1% | +10.0% | +9.1% | +27.1% | +6.6% | +6.2% | +5.8% | +4.8% | +2.6% | +2.5% | +2.5% | +2.4% | +1.8% | — |
| Dividends paid | 8.0 | 8.5 | 5.5 | 6.1 | 6.2 | 6.5 | 6.6 | 7.3 | 7.7 | 8.0 | 8.0 | 8.4 | 8.7 | 9.0 | 9.2 | 9.5 | 9.8 | 9.8 |
| Share buybacks | 10.0 | 0.5 | 0.0 | 1.0 | 9.0 | 8.2 | 16.3 | 5.0 | 5.0 | 12.2 | 8.9 | 0.0 | 0.0 | 2.0 | 0.0 | 0.0 | — | — |
| Dividends ÷ net income | 97.9% | 105.4% | 64.3% | 73.7% | 62.3% | 44.8% | 29.9% | 101.4% | 35.9% | 71.5% | 50.2% | 92.1% | 39.7% | 28.6% | 436.4% | 118.4% | 125.7% | 242.8% |
Recent dividend announcements
- Pfizer board approves Q4 2026 dividend Source
Compare with peers
- Merck & Co. dividends
- Astrazeneca PLC dividends
- Bristol Myers Squibb dividends
- Novo Nordisk A S dividends
- Lilly (Eli) dividends
Head to head: MRK vs PFEAZN vs PFEBMY vs PFELLY vs PFE
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies